Geneos Wealth Management’s Myriad Genetics MYGN Stock Holding History

Geneos Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-250	Closed	-$4K	–	2370
2022 Q2	$4K	Hold	250	–	–	﹤0.01%	2264
2022 Q1	$6K	Hold	250	–	–	﹤0.01%	2278
2021 Q4	$6K	Hold	250	–	–	﹤0.01%	2355
2021 Q3	$7K	Hold	250	–	–	﹤0.01%	2355
2021 Q2	$7K	Hold	250	–	–	﹤0.01%	2340
2021 Q1	$7K	Hold	250	–	–	﹤0.01%	2539
2020 Q4	$7K	Hold	250	–	–	﹤0.01%	2370
2020 Q3	$3K	Hold	250	–	–	﹤0.01%	2325
2020 Q2	$2K	Hold	250	–	–	﹤0.01%	2370
2020 Q1	$3K	Hold	250	–	–	﹤0.01%	2184
2019 Q4	$6K	Hold	250	–	–	﹤0.01%	2146
2019 Q3	$7K	Hold	250	–	–	﹤0.01%	2009
2019 Q2	$6K	Hold	250	–	–	﹤0.01%	2076
2019 Q1	$8K	Hold	250	–	–	﹤0.01%	1910
2018 Q4	$7K	Sell	250 -300	-55%	-$10.8K	﹤0.01%	1889
2018 Q3	$25K	Buy	550 +300	+120%	+$13.3K	﹤0.01%	1480
2018 Q2	$9K	Hold	250	–	–	﹤0.01%	1764
2018 Q1	$7K	Hold	250	–	–	﹤0.01%	1771
2017 Q4	$8K	Buy	+250	New	+$8.43K	﹤0.01%	1708

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Geneos Wealth Management's MYGN Position: Q3 2022 in Review

Geneos Wealth Management sold out of Myriad Genetics (MYGN) in Q3 2022, closing a stake of 250 shares — an estimated $4K sold.

Geneos Wealth Management first reported a position in MYGN in Q4 2017 and held it in 19 quarters. The position peaked at $25K in Q3 2018. 191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

Geneos Wealth Management reported no remaining Myriad Genetics position as of Q3 2022 after selling out during the quarter.
Geneos Wealth Management sold 250 Myriad Genetics shares in Q3 2022, an estimated $4K.
Geneos Wealth Management first reported a position in Myriad Genetics in Q4 2017 and held it in 19 quarters.
Geneos Wealth Management's Myriad Genetics position peaked at $25K in Q3 2018.
191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.